Initial clinical outcomes of 177Lu-PSMA-I&T therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) - Singapore experience.

Conclusions: Our findings show that 177Lu-PSMA-I&T therapy has early promising response rates and low toxicity in men with mCRPC who have progressed after conventional treatments in our local setting.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Thang, S. P., Lam, W. W. C., Tong, A. K. T., Yan, X., Huang, H. L., Ng, D. C. E. Tags: Prostate Therapy II Source Type: research